Antibody-Drug Conjugates in Non-small Cell Lung Cancer - PubMed
5 hours ago
- #Clinical Trials
- #Non-small Cell Lung Cancer
- #Antibody-Drug Conjugates
- ADCs are complex molecules consisting of a monoclonal antibody, linker, and cytotoxic payload.
- They enable selective delivery of cytotoxic agents to tumor cells via antigen binding, internalization, and payload release.
- ADCs have been evaluated in phase II/III trials for advanced NSCLC, both oncogene-addicted and non-addicted tumors.
- Ongoing trials are exploring their use in first-line settings and earlier disease stages.
- Improved patient selection is needed to maximize benefit and limit toxicity, considering clinical characteristics, pharmacogenomics, and treatment sequencing.
- Understanding resistance mechanisms and developing predictive biomarkers are crucial for clinical practice.